{
  "id": "d023cf71ffac4d73",
  "title": "Spero Announces NDA Resubmission of Tebipenem HBr by GSK to the FDA for the Treatment of Complicated Urinary Tract Infections , Including Pyelonephritis",
  "description": "20251219T134500Z",
  "content": "",
  "source": "manilatimes.net",
  "source_url": "https://www.manilatimes.net/2025/12/19/tmt-newswire/globenewswire/spero-announces-nda-resubmission-of-tebipenem-hbr-by-gsk-to-the-fda-for-the-treatment-of-complicated-urinary-tract-infections-including-pyelonephritis/2246995",
  "published_at": "20251219T134500Z",
  "fetched_at": "2025-12-20T00:22:03.659749+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [
    "fda"
  ],
  "location": "Philippines",
  "raw_data": {
    "url": "https://www.manilatimes.net/2025/12/19/tmt-newswire/globenewswire/spero-announces-nda-resubmission-of-tebipenem-hbr-by-gsk-to-the-fda-for-the-treatment-of-complicated-urinary-tract-infections-including-pyelonephritis/2246995",
    "url_mobile": "https://www.manilatimes.net/2025/12/19/tmt-newswire/globenewswire/spero-announces-nda-resubmission-of-tebipenem-hbr-by-gsk-to-the-fda-for-the-treatment-of-complicated-urinary-tract-infections-including-pyelonephritis/2246995/amp",
    "title": "Spero Announces NDA Resubmission of Tebipenem HBr by GSK to the FDA for the Treatment of Complicated Urinary Tract Infections , Including Pyelonephritis",
    "seendate": "20251219T134500Z",
    "socialimage": "https://www.manilatimes.net/manilatimes/uploads/images/2025/12/19/874523.jpg",
    "domain": "manilatimes.net",
    "language": "English",
    "sourcecountry": "Philippines"
  }
}